{"id":"NCT03374956","sponsor":"Mayo Clinic","briefTitle":"Individualized Obesity Pharmacotherapy","officialTitle":"Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-11","primaryCompletion":"2022-05-26","completion":"2022-05-26","firstPosted":"2017-12-15","resultsPosted":"2023-07-18","lastUpdate":"2023-07-18"},"enrollment":193,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity"],"interventions":[{"type":"DRUG","name":"Phentermine-Topiramate","otherNames":["Qsymia"]},{"type":"DRUG","name":"Liraglutide","otherNames":["Saxenda"]},{"type":"DRUG","name":"Naltrexone/bupropion","otherNames":["Contrave"]},{"type":"DRUG","name":"Phentermine","otherNames":["Adipex-P","Lomaira"]}],"arms":[{"label":"Intervention group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.","primaryOutcome":{"measure":"Change in Total Body Weight","timeFrame":"baseline to 12 weeks","effectByArm":[{"arm":"Intervention Group","deltaMin":-7.7,"sd":null},{"arm":"Control Group","deltaMin":-6.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33759389"],"seeAlso":["https://www.mayo.edu/research/clinical-trials"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":93},"commonTop":["During study"]}}